Heart failure drug combo may improve valve function

NCT ID NCT07379788

Completed Disease control Sponsor: Rehab Werida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study in 180 heart failure patients compared the effects of taking Entresto alone versus Entresto plus a second drug (empagliflozin) on mitral valve function and heart pumping ability. Participants had heart failure with reduced ejection fraction and some degree of functional mitral regurgitation. The study measured changes in heart structure and function using echocardiography.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacubitril/Valsartan (Entresto) and Empagliflozin
What this could lead to: If successful, this could show that adding an SGLT2 inhibitor to standard ARNI therapy improves heart valve function and heart pumping ability in people with heart failure.
What could go wrong: This is a small, completed study with no phase designation, so results may not be definitive or widely applicable. The outcomes are imaging-based measures, not long-term clinical benefits like survival or hospitalizations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FUNCTIONAL MITRAL REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure mitral valve insufficiency systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Madinah Cardiac Center

Madinah, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.